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Uveal melanoma (UM) is recognized as the most common intraocular malignancy and the
secondmost common form of melanoma. Nearly 50% of UM patients develop untreatable
and fatal metastases. The 48-member nuclear receptor (NR) superfamily represents a
therapeutically targetable group of transcription factors known for their regulation of key
cancer pathways in numerous tumor types. Here, we profiled the expression of the
48 human NRs by qRT-PCR across a melanoma cell line panel including 5 UM lines,
9 cutaneous melanoma (CM) lines, and normal primary melanocytes. NR expression
patterns identified a few key features. First, in agreement with our past studies identifying
RXRg as a CM-specific marker, we found that UM cells also exhibit high levels of RXRg
expression, making it a universal biomarker for melanoma tumors. Second, we found
that LXRb is highly expressed in both UM and CM lines, suggesting that it may be a
therapeutic target in a UMmetastatic setting as it has been in CMmodels. Third, we found
that RARg, PPARd, EAR2, RXRa, and TRa expressions could subdivide UM from CM.
Previous studies of UM cancers identified key mutations in three genes: GNAQ, GNA11,
and BRAF. We found unique NR expression profiles associated with each of these UM
mutations. We then performed NR-to-NR and NR-to-genome expression correlation
analyses to find potential NR-driven transcriptional programs activated in UM and CM.
Specifically, RXRg controlled gene networks were identified that may drive melanoma-
specific signaling and metabolism. ERRa was identified as a UM-defining NR and genes
correlated with its expression confirm the role of ERRa in metabolic control. Given
the plethora of available NR agonists, antagonists, and selective receptor modulators,
pharmacologic manipulation of these NRs and their transcriptional outputs may lead to a
more comprehensive understanding of key UM pathways and how we can leverage them
for better therapeutic alternatives.
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Introduction
Uveal melanoma (UM) is the most common form of intraocular cancer in adults and comprises
about 5% of all malignant melanoma diagnoses (1). UM tumors differ from cutaneous melanomas
(CM) in that they arise from melanocytes of the choroid, ciliary body, and iris, defined as the
uvea. Although there are effective therapeutic approaches for treating primary uveal tumors, more
than 50% of patients exhibit hematogenous spread and metastatic disease, most often to the liver
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(~80–90%of cases) (2). OnceUMdisease has disseminated, thera-
peutic options are severely limited and average survival rates range
from 2 to 8months (3).
One of the major factors hampering development of therapeu-
tic options for metastatic UM is the lack of discernible driver
mutations. Unlike CMs, which frequently harbor BRAFV600E or
NRAS mutations, only ~5% of UMs (specifically, only UMs orig-
inating from the iris) exhibit BRAFV600E mutations, and NRAS
mutations are typically not observed in UM tumors (4). Recent
mutational profiling studies ofUMhave identifiedmutually exclu-
sive, activatingmutations in two G protein coupled receptor alpha
subunits, GNAQ and GNA11, in more than 80% of profiled UM
tumors (5). These mutations appear to be relatively UM spe-
cific and are only found in about 5% of cases in other tumor
types (6).
The nearly ubiquitous presence of the GNAQ and GNA11
mutations in UM suggests that they would make an effective
therapeutic target, but functional studies of these mutations
have noted them to be relatively weak oncoproteins that require
other genetic alterations (including p53 and p16/CDK4/RB1 path-
way inactivation) to transform immortalized melanocytes (7).
Some success has been seen with targeting of downstream tar-
gets of GNAQ/GNA11 (specifically combined PKC and MEK
inhibition), suggesting that indirect targeting of these muta-
tions may be more effective (8). Recent advances have been
made in understanding the underlying mechanism of the GPCR
alpha subunit’s oncogenic activity, specifically the identifica-
tion of the transcriptional coactivator yes-associated protein 1
(YAP 1) as a pro-proliferative oncogene and potential therapeutic
target (9).
The nuclear receptor (NR) superfamily of transcription factors
includes 48 members, most of which activate complex transcrip-
tional programs via ligand binding (10). NRs regulate numer-
ous physiological programs including developmental, homeo-
static, proliferative, reproductive, and metabolic pathways (11).
In a cancer context, NRs have been validated as pro-proliferative
and oncogenic drivers in many tumor types including breast,
ovarian, prostate, endometrial, and hematological malignancies
(12, 13). In these diseases, NRs have proven to be effective
therapeutic targets with numerous drugs targeting many NRs
including estrogen receptor (ER) in breast, ovarian, and endome-
trial cancers, androgen receptor (AR) in prostate tumors, and
glucocorticoid receptor (GR) in some hematological malignancies
(14). In previously published work studying lung cancer, NR
expression analysis has been successfully used to develop a prog-
nostic signature for both survival and progression free survival
and to identify potential therapeutic drug targets in pre-clinical
models (15).
Nuclear receptors have also been noted as having tumor sup-
pressive functions including VDR’s protective function in colon
cancer (16); PPARg’s activation in reducing tumorigenicity in
many cancer tissue types (17); TR4 and RARb as tumor sup-
pressors in prostate (18, 19), and NUR77 and NOR1 as tumor
suppressors in AML (20). Given the extensive roles that NRs play
in the maintenance of normal development and physiology as
well as the emerging understanding of NRs in oncogenic path-
ways, we set out to investigate how NR expression and activity
may be leveraged to discover novel diagnostic, prognostic, and
therapeutic alternatives in UM.
The expression and activity of NRs in UMs have been, to date,
completely unstudied. To address this issue, we have used high-
throughput qRT-PCR to profile the expression of the 48 members
of the NR superfamily in various UM cell lines derived from both
primary and metastatic lesions and in a normal melanocyte cell
line. Based on these results, we report UM-specific NR expression
patterns as well as pharmacologically targetable NR-regulated
gene networks that could be driving proliferative or oncogenic
signaling in UM.
Materials and Methods
Cell Lines and RNA Extractions
All UM cell lines were a kind gift from Dr. Jerry Niederkorn at
UT Southwestern and were grown as originally described (21).
CM cell lines were received from the NCI, NIH. Cell line identity
was confirmed by fingerprinting and compared to standardswhen
available. Primary adult humanmelanocytes were purchased from
Cascade Biologics andwere grownper the company’s instructions.
Cell pellets were processed for RNA extraction using the RNeasy
kit, according to the manufacturer’s protocol. Extracted RNA was
quantified, aliquoted, and stored at  80°C and used to make the
corresponding cDNA with Invitrogen’s (Carlsbad, CA, USA) First
Strand kit.
qRT-PCR and Data Analysis
Analysis of NR expression (mRNA) was performed in tripli-
cate using the TaqMan-based efficiency-corrected cycle threshold
method with 12.5 ng cDNA per reaction for 50 cycles in an ABI
7900HT sequence detection system (Applied Biosystems, Foster
City, CA, USA) as previously described (22). NR mRNAs with
cycle times >35 were determined to be below detection. Primer
concentrations were 75 nM for 18S rRNA and 300 nM for NR
primers; probes were added at 250 nM. The sequences of the
validated primer/probe sets for the 48 human NRs are available
at www.nursa.org under the rapid release tab. Universal cDNA
standards generated from human adult RNA (BD Clontech, Palo
Alto, CA, USA) were used for analysis of all receptors except CAR,
FXRb, PXR, SHP, DAX-1, ERb, LRH-1, PNR, SF-1, and TLX,
which were too limited in expression to use the universal RNA set.
For these receptors, commercially available tissue-specific total
RNA standards derived from cell lines or adult organ donors
were used from liver, ovary, eye, adrenal, and brain, as appropri-
ate. qRT-PCR data were analyzed using ABI instrument software
SDS2.1. Baseline values of amplification plots were set automati-
cally, and threshold values were kept constant to obtain normal-
ized cycle times and linear regression data. Because PCR efficien-
cies for each receptor primer set vary, individual receptor PCR
efficiencies were determined to permit receptor-to-receptor com-
parisons. PCR efficiencies were calculated from the slope of the
resulting standard curves as reported previously (11). Normalized
mRNA levels are expressed as arbitrary units andwere obtained by
dividing the averaged, efficiency-corrected values for NR mRNA
expression by that for 18S RNA expression for each sample.
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Microarray Data
All microarray data were obtained from published datasets avail-
able at the GEO Database (http://www.ncbi.nlm.nih.gov/gds/)
(23–25). The data were generated using two different platforms,
Affymetrix Human Genome U133 Plus 2.0 Array (63 UM tumors
and nine NCI-60 melanoma cell lines) and Illumina HumanHT-
12 V4.0 expression beadchip (three UM cell lines). Data were
compiled and a consensus list of 17,700 unique genes was further
analyzed as described in the manuscript text.
Statistical Methodologies
Dendrograms were generated using R Statistical Software. Analy-
sis parameters included distance calculations using a Manhattan
methodology and Ward’s method for cluster aggregation. Cor-
relation coefficients for comparisons between data were cal-
culated using Pearson Correlation. p-Values for comparisons
between groups of measurements were performed using Student’s
t-tests. Bonferroni Corrections were used to account for multiple-
hypothesis testing as appropriate.
Gene Ontology Analysis
Correlation coefficients (Pearson) were calculated for each gene
and the NR in question (either ERRa or RXRg). Lists were then
culled to retain the most significantly positively correlated genes
(cutoff of r> 0.6was used). Culled lists were input into gene ontol-
ogy (GO) analysis tool GOrilla and GO analyses were performed
as described (26).
Results
NR Expression in Melanomas
To investigate the expression levels of the human NR superfamily
(n= 48) inUM,we performed high-throughput qRT-PCR expres-
sion analysis across a cell line panel consisting of five UM cell
lines, nine CM cell lines from the NCI-60 (27), and one primary
melanocyte control (Figure 1). A heat map was generated to
display the results and it was seen that several receptors including
SF-1, SHP, TLX, PR, and HNF4a are either expressed at very low
levels or completely unexpressed across the panel, suggesting that
they do not play a large role in either CM or UM. Other receptors,
such as COUPT-FII, LXRb, and RXRg, were found to be strongly
expressed across all the samples analyzed. GR, NOR1, NURR1,
PPARa, TR2, and TR4 were also expressed in all samples, but at
more moderate levels.
Data quality was assessed by comparison to 63 previously pub-
lished microarray profiles generated from patient UM samples
(Figure S1 in SupplementaryMaterial) (24). In this comparison, it
was seen that NRs unexpressed in the qRT-PCR dataset reported
here were also unexpressed in the patient dataset. Likewise, NRs
found highly expressed in the qRT-PCR dataset were generally
well expressed in the UM patient samples. Examples of these
NRs are shown on Figure S1 in Supplementary Material. Overall,
Spearman rank correlation of the expression levels of the 48 NRs
between the two datasets was found to be 0.619 (p< 0.0001), sug-
gesting that the data presented here forUM lines are representative
of findings in clinical UM samples.
Hierarchical Clustering of Cell Lines by
NR Expression
To visualize relationships within the dataset, unsupervised hierar-
chical clustering analyseswere performed on the qRT-PCRdataset
for both the 13 cell lines and the 48 NRs (Figure 1). For these
analyses, distance matrices were calculated using the Manhattan
distance methodology and clusters were aggregated based on
Ward’s method. First, we observed that the expression of the 48
NRs can properly segregate the UM lines from the CM lines.
The known mutational spectrum of CM and UM would suggest
that these two types of melanoma differ from each other, and
the unique NR expression signatures seen here, support this idea.
As would be expected, NR expression does subdivide the normal
melanocyte from the tumor cell lines, but interestingly places the
melanocyte in closer proximity to the uveal cluster.
Analysis of the clusters generated by aggregation of the NR
probes found several levels of distinctions. Primary subdivisions
include a large group of receptors that are either lowly expressed
or fairly uniformly expressed, and a second group of receptors
that are differentially expressed between CM and UM samples.
Interestingly, two NRs (LXRb and RXRg) were particularly dis-
tinct from the other NRs in the dataset due to their exceptionally
high expression. Previously published work from our group noted
that RXRg expression is very high inCMcell lineswhile essentially
unexpressed in every other tissue type in the NCI-60 cancer cell
line panel (27). High levels of RXRg expression are similarly seen
in UM. When the UM samples were clustered together with the
previously published NCI-60 NR expression data, it was found
that RXRg expression defined a “melanoma cluster,” which con-
tained both UM and CM samples (Figure S2 in Supplementary
Material).
Differential Expression of NRs in
UM Compared to CM
We next examined NRs differentially expressed between UM and
CM (Figure 2). First, three NRs (RARg, PPARd, and EAR2) were
found to have significantly lower expression levels in CM than in
UM cell lines. Comparison to the melanocyte control suggested
that the UM samples had retained “normal” expression of these
receptors while expression had been lost in the CM samples.
Conversely, it was found that RXRa expression was lower in UM
than in CM or in the melanocyte control, suggesting UM had
specifically lost RXRa expression. Analysis of TRa levels found
that UM lines retained expression of this NR similar to that of the
melanocyte, but that expression of TRa was significantly higher
in CM. By contrast, REVerb an expression appears to be lost
specifically in UM. As was previously mentioned, LXRb is highly
expressed across all melanoma samples, but is expressed signifi-
cantly higher in UM samples. This finding is particularly notable
since LXRb agonists have been shown to reduce proliferative and
metastatic potential in CM pre-clinical mouse models (28).
Clusters of Co-Expressed NRs
To better understand the relationships between the NRs them-
selves within the melanoma panel, we calculated correlation
coefficients (performed as before) for all possible pairwise combi-
nations of the 48 NRs. The results of this unsupervised clustering
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FIGURE 1 | Nuclear receptor expression in melanomas. Clustered
heat map representation of mRNA expression levels of the 48 human
NRs in a panel of human uveal melanoma (n= 5) and cutaneous
melanoma (n= 9) cell lines as measured by qRT-PCR. Additionally, a
melanocyte was included as a normal comparator. Unsupervised
hierarchical clustering (Distance calculations: Manhattan, Aggregation
method: Ward’s) was performed on the NRs (columns) and cell line
samples (rows, colored according to key). qRT-PCR data were quantified
using standard curves and normalized to 18S as described in Section
“Materials and Methods.” Data are color coded such that relatively highly
expressed NRs are dark blue while lowly or unexpressed receptors (cycle
time >35) are white.
analysis are shown as a heat map in Figure 3. Several clusters of
strongly positive correlations could be seen, including a cluster
containing receptors identified as differentially regulated between
CM and UM. The CM-specific cluster included EAR2, REV-ERb,
RARg, NOR1, andGCNFwhile theUM-specific cluster contained
LXRb, ERRb, TR2, and ERRa. These pockets of strong correla-
tion suggest transcriptional and/or functional interconnections
within these receptor subgroups and within specific melanoma
subtypes.
Differential Expression of NRs Across UM
Finally, we compared NR profiles across the different UM cell
lines (Figure 4). Because UM metastatic disease is essentially
fatal, we were particularly interested in identifying metastasis-
specific NR expression patterns. Initially, we chose to compare NR
expression in the cell line pair MEL270 (primary) and OMM2.3
(metastasis), both of which were derived from the same patient.
Several genes were found differentially expressed between the pair
with the most significant, liganded NRs highlighted in Figure 4A.
ERa and GR expressions were found to be lost in the metastasis-
derived OMM2.3 versus the primary MEL270. Conversely, LXRb
and PPARg expressions were either significantly lower (LXRb)
or completely undetected (PPARg) in the primary while robust
expression was seen in the metastatic line, suggesting that these
genes were up-regulated during the metastatic process and may
be essential for retention of proliferative capacity or for survival at
distant anatomical sites.
Within the UM panel, three cell lines were derived from pri-
mary tumors (OCM3, MEL270, and OCM1) and two cell lines
were derived from metastatic lesions (OMM1 and OMM2.3).
Comparison between these two groups found that NGFIBwas up-
regulated in the metastatic lines versus the primary tumor lines
and the melanocyte control line (Figure 4B). There were several
other NRs that were up-regulated in the metastatic group, but the
small sample size and heterogeneity among primary tumor lines
precluded statistical significance.
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FIGURE 2 | Uveal versus cutaneous melanoma NR expression
patterns. Patterns of mRNA expression across the cell line panel for
select receptors. p-Values are shown for the comparison of the
expression level of the indicated nuclear receptor between uveal and
cutaneous melanoma cell lines. Calculations were performed using a
Student’s t-test and were Bonferroni-corrected for to account for
multiple-hypothesis testing. (A) Three receptors (RARg, PPARd, and
EAR2) are lost in cutaneous melanoma but retained in the uveal
melanoma samples (versus melanocyte expression). (B) (Top) RXRa is
lost in uveal melanoma samples. (Middle) TRa is overexpressed by
cutaneous melanomas. (Bottom) LXRb expression is higher in uveal
melanoma samples.
Examples of all three of the key UMmutations are represented
in the cell line panel (Table 1). Because GNAQ, GNA11, and
BRAFmutations are mutually exclusive in clinical samples (5), we
identified potentially mutation-specific NR expression patterns
(Figure 4C). First, we found that the GNA11 mutant cell line
OMM1 showed significant overexpression of NOR1 versus the
rest of the panel. Comparisons between the BRAF mutant UM
lines OCM1 and OCM3 and the rest of the panel found that the
BRAF mutants retained expression levels of AR comparable to
the melanocyte while the other cell lines had lost AR expression.
Finally, it was found that both OMM2.3 and MEL270 (GNAQ
mutants) had almost completely lost RORa expression while the
other cell lines maintained RORa expression at levels comparable
to the primary melanocyte line.
NR-Driven Gene Networks in UM
Finally, because NR activity has been largely unstudied in UM, we
examined publically available microarray profiles generated from
both UM and CM cell lines (23, 25) to identify gene networks
that might be NR-regulated in the melanoma context. For these
analyses, we selected two liganded NRs (ERRa and RXRg) that are
expressed across the melanoma panel and that correlated strongly
with our qRT-PCRdata for these same cell lines (r= 0.82 for ERRa
and 0.7 for RXRg). Lists ofmicroarray probes positively correlated
with either ERRa or RXRg expression patterns were generated,
culled to the top 400 genes correlating with each receptor (Table
S1 in Supplementary Material), and subjected to gene ontology
(GO) analysis using publically available GO analysis tool Gorilla
(26). Top GO terms associated with ERRa and RXRg are shown
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FIGURE 3 | NR-to-NR pairwise correlation comparisons. Pairwise Pearson
correlation coefficient (PCC) analysis of the nuclear receptors. Hierarchical
clustering analysis was performed as in Figure 1. Positive correlations are
depicted in orange with the strongest intensities corresponding to higher
correlations (0.95 was the highest pairwise correlation). Similarly, negative
correlations are depicted in blue tending toward white as they become less
intense. The range of positive correlations (0–0.95) was greater than the range
of negative correlations (0 to  0.64).
in Tables 2 and 3, respectively. For RXRg (the main differentiator
between melanomas and other cancers), top GO terms included
numerous lipid and basal metabolism associated functions as
expected (10), suggesting RXRg may be regulating these func-
tions within a melanoma context. Furthermore, four GO terms
associated with RXRg pertained to peroxisome activity [RXRs
and PPARs have a well-established relationship (10)], suggesting
RXRg could acquire activities within a melanoma setting. One of
the genes defining the UM cluster was ERRa, a known regulator
of metabolic pathways (29). Predictably, 11 of the top 12 GO
terms involved metabolic regulation, indicating that ERRa may
contribute to regulation of metabolism in UM, a role that may be
pharmacologically targetable via inverse agonists of ERRa.
Discussion
In this study, we measured expression levels of the 48 human
NRs by qRT-PCR across a panel of UM cell lines and a nor-
mal melanocyte control to expand on our original work across
the NCI-60 panel. We demonstrated that UM (like CM) is dis-
tinguished from other cancer cell lines by high expression of
RXRg, an NR that we previously reported separates melanomas
from other cancers. Furthermore, UM and CM can be differen-
tiated based solely on their NR expression profiles with several
NRs differentially expressed between the two (including RARg,
PPARd, EAR2, RXRa, and TRa). Our results confirm the dis-
tinction of UM and CM as separate diseases in line with their
differing mutational profiles. We also examined whether there are
NRs preferentially expressed in the different mutational subtypes
of UM (GNA11Q209L, BRAFV600E, and GNAQQ209P) and identi-
fied receptors (NOR1, AR, and RORa, respectively) exhibiting
mutation-specific expression patterns.
Because of the particular importance of metastases within UM,
we compared primary-derived and metastasis-derived UM cell
lines to identifyNRs thatmight be playing specific roles within the
metastatic context. We discovered that NGFIB was up-regulated
in UMmetastatic cell lines versus primary-derived UM cell lines.
Although this was the only NR that met our statistical thresh-
old, it is notable that two other members of the NR4 family
(NOR1 and NURR1) also showed generally higher expression
in the metastasis-derived UM cell lines. The role of NR4 family
members in cancer is controversial as it has been noted to be pro-
proliferative in some contexts and tumor suppressive in others
(20). One other notable NR that trended toward higher expression
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FIGURE 4 | Identification of NR expression patterns within uveal
melanoma subtypes. (A) Comparisons were made between replicate data
generated from UM cell line pair OMM2.3 (metastasis-derived) and MEL270
(primary-derived) with p-values calculated through a Bonferroni-corrected
Student’s t-test. ERa and GR expressions were lost in the metastatic line (top)
while LXRb and PPARg expressions were higher in the metastasis (bottom).
(B) NGFIB expression was found higher in the metastasis-derived UM cell
lines versus the primary-derived UM lines (p-value from corrected t-test).
(C) Receptor expression was compared between the different mutational states
of UM. (Top) NOR1 was found overexpressed in the GNA11 mutant, (middle) AR
expression was retained in the BRAF mutants, and (bottom) RORa expression
was lost in the GNAQ mutant cell lines.
TABLE 1 |Mutation status of cell lines studied.
Cell line Gq mutant G11 mutant BRAF mutant
Melanocytes WT WT WT
OCM1 WT WT V600E
OCM3 WT WT V600E
OMM1 WT Q209L WT
OMM2.3* Q209P WT WT
Mel270* Q209P WT WT
LOXIMVI WT WT V600E
M14 WT WT V600E
MALME-3M WT WT V600E
MDA-MB-435 WT WT V600E
SK-MEL-2 WT WT V600E
SK-MEL-28 WT WT V600E
SK-MEL-5 WT WT V600E
ACC-257 WT WT V600E
UACC-62 WT WT V600E
*Indicates cell lines from same patient.
The cell lines used in this study are listed, along with their mutation status for GNAQQ209P
(Gq), GNA11Q209L (G11), and BRAFV600E (BRAF). WT, wild type.
in the metastasis-derived uveal lines was PPARg, which has been
noted in many cancer models to be anti-proliferative upon ligand
activation (17).
Finally, we examined NR-to-NR correlation patterns as well
as NR-to-genome correlation patterns to identify receptors that
might be interacting with each other and to identify networks of
genes that certain, key NRs might be controlling within the UM
context. ERRa was one of the NRs that differentiated the UM clus-
ter from theCMcluster, and is particularly important given its role
as a therapeutic target in other cancers (particularly breast cancer)
and the growing availability of ERRa-targeted therapeutics (30)
including inverse agonists, which lower the receptor’s constitutive
activity.
Analogous studies conducted previously by our group and
others have successfully utilized NR expression profiles to sub-
divide between different cancer types. It has been demonstrated
that expression profiles of the 48 NRs alone can properly dis-
tinguish between cancers of vastly different origins (within the
NCI-60 panel) (27), between small-cell and non-small-cell lung
cancers (15), and between different types of thyroid cancers (31).
Here, we further add the differentiation by NRs between UM
and CMs, suggesting that the use of NR expression patterns may
be broadly applicable as a tool to categorize different cancers
and histological groupings. Given their key roles in regulation
of global cellular signaling processes and in cellular development
pathways, it is not surprising that NRs play such a central role
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TABLE 2 | ERR alpha associated gene ontology (GO) terms.
GO term Description p-Value FDR
q-value
GO:0044238 Primary metabolic process 2.35E-05 3.07E-01
GO:0071704 Organic substance metabolic
process
5.93E-05 3.88E-01
GO:0044260 Cellular macromolecule metabolic
process
8.73E-05 3.81E-01
GO:0044237 Cellular metabolic process 1.03E-04 3.37E-01
GO:0043170 Macromolecule metabolic process 1.93E-04 5.05E-01
GO:0090304 Nucleic acid metabolic process 2.28E-04 4.98E-01
GO:0006139 Nucleobase-containing compound
metabolic process
2.59E-04 4.84E-01
GO:0016070 RNA metabolic process 4.45E-04 7.28E-01
GO:0046483 Heterocycle metabolic process 4.85E-04 7.05E-01
GO:0006725 Cellular aromatic compound
metabolic process
5.08E-04 6.65E-01
GO:0006366 Transcription from RNA polymerase
II promoter
6.71E-04 7.98E-01
GO:0009058 Biosynthetic process 9.59E-04 1.00E+ 00
Gene ontology descriptions of genes positively correlated to ERR alpha expression levels
in UM are shown, along with the corresponding p-value and false discovery rate q-values.
TABLE 3 | RXR gamma associated gene ontology (GO) terms.
GO term Description p-Value FDR
q-value
GO:0044255 Cellular lipid metabolic process 4.39E-06 5.75E-02
GO:0006629 Lipid metabolic process 1.36E-05 8.89E-02
GO:0008610 Lipid biosynthetic process 3.67E-05 1.60E-01
GO:0006631 Fatty acid metabolic process 3.87E-05 1.27E-01
GO:0032787 Monocarboxylic acid metabolic
process
1.20E-04 3.15E-01
GO:0071616 Acyl-coA biosynthetic process 1.26E-04 2.75E-01
GO:0035384 Thioester biosynthetic process 1.26E-04 2.36E-01
GO:0019752 Carboxylic acid metabolic
process
2.26E-04 3.70E-01
GO:0006082 Organic acid metabolic process 2.81E-04 4.09E-01
GO:0032868 Response to insulin 3.98E-04 5.21E-01
GO:0006625 Protein targeting to peroxisome 5.38E-04 6.40E-01
GO:0072663 Establishment of protein
localization to peroxisome
5.38E-04 5.87E-01
GO:0072662 Protein localization to
peroxisome
5.38E-04 5.42E-01
GO:0043436 Oxoacid metabolic process 5.56E-04 5.20E-01
GO:0006790 Sulfur compound metabolic
process
6.29E-04 5.48E-01
GO:0043574 Peroxisomal transport 6.57E-04 5.38E-01
GO:0006633 Fatty acid biosynthetic process 8.21E-04 6.32E-01
Gene ontology descriptions of genes positively correlated to RXR gamma expression
levels in UM are shown, along with the corresponding p-value and false discovery rate
q-values.
to the identities of these cell types, even within a dedifferentiated
cancer state.
It is of significant interest that several NRs are differentially
expressed between UM and CM tumors. Particularly, the findings
RARg, PPARd, EAR2, TRa, and LXRb that are retained in UM at
levels comparable to the melanocyte while being reduced or lost
in CM suggests that there may be opportunities for NR-directed
therapeutic interventions in UM that are not available in CM due
to CM-specific loss of these receptors. It is also worth noting
that the UM-specific loss of RXRa expression. Because RXRa
is a heterodimeric binding partner for many NRs, lower RXRa
expressionmight suggest indirect downregulation ofNR signaling
in UM tumors.
It has recently been reported that metastatic CM can be inhib-
ited by administration of LXRb agonists in pre-clinical models
of CM (28). Here, we report that LXRb receptor levels are even
higher in UM samples than the levels observed in CM samples.
Given the known differences between UM and CM tumors, it will
be important for future studies to examine whether or not LXRb-
directed therapies or other NR ligand strategies will be effective in
controlling UMmetastatic disease in vivo.
Melanoma is an aggressive, highly metastatic disease that is
notoriously difficult to treat using standard cytotoxic agents (32).
Mechanistic studies have found that CM cells achieve their hall-
mark chemoresistance through genome-scale reprogramming of
proliferation and survival pathways during disease progression.
Given these findings, it is not surprising that many modern
therapeutic strategies involve induction of wholesale changes in
the transcriptome of CM cells through epigenetic modulation to
overcome these anti-apoptotic and pro-proliferative pathways (33,
34). Although much work has been done in CM, far fewer studies
have investigated ocular-derived UMs where metastatic disease is
equally as fatal (3).
Mutational profiling of UM has identified mutually exclu-
sive, UM specific, activating mutations in two paralogs (GNAQ
and GNA11) in more than 80% of UM cases. Although these
mutations would seem obvious targets for therapeutic interven-
tion, GNAQ/11 mutations have not been amenable to therapeu-
tic development in UM and recent work has instead focused
on inhibiting downstream events and gene networks driven by
these mutations (9, 35). As an example, combination therapy
with inhibitors of GNAQ/11 downstream target protein kinase C
(PKC) and MEK has been shown to inhibit the in vitro growth
of GNAQ/11 UM mutant cell lines (8). Another recently iden-
tified downstream target of GNAQ/11 mutants is YAP1 and a
YAP1 inhibitor, verteporfin, has also been shown to be effective
inhibiting UM growth in xenograft models (35). However, as was
pointed out in a recent preview opinion from Field and Barbour
(36), it is important to note that these inhibitors alone will likely
be insufficient for treatingUMmetastases as GNAQ/11mutations
are only weakly oncogenic being unable to transform immortal-
ized melanocytes without additional, cooperating mutations (7).
Recent clinical trial results using the MEK inhibitor selumetinib
in metastatic UM patients underscore their opinion as there was
no overall survival benefit (37).
As transcription factors, activated NRs are extremely effective
in eliciting widespread physiologic changes in cells through alter-
ation of the transcriptional output and architecture of the genome
(38). One of the most striking examples of ligand-mediated NR
activity comes from studies of estradiol’s effects on the transcrip-
tome of an ER-positive breast cancer cell line. They report nearly
23,000 transcripts (equivalent to more than 25% of total cellular
transcriptomic output) that are altered during ER activation (39).
Other ligand/receptor combinations known to elicit broad-scale
expression changes includemifepristone/progesterone receptor in
endometrial tissue (40) and T0901317/liver X receptors in the
human monocytic cell line THP-1 (41). Defining which NRs
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might be playing a role in transcriptional reprogramming during
UM onset and progression, as we have begun to do here, should
catalyze a better understanding and targeting of this disease.
Overall, it will be interesting to see how NR expression patterns
correlate with clinical disease progression in the future release
of the UM TCGA dataset, to then design NR-driven therapeutic
strategies.
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